Pharma Mirror

NOVEMBER 30, 2020

Pan-JAK inhibitors have been developed and tested in clinical trials, approved and commercialised for many different indications but mainly for the treatment of chronic inflammatory conditions associated with an overactive immune response. VR588 was previously developed by Vectura as part of its former speciality pharma pipeline.

Immunization 52

Immunization 52

Pharma Mirror

NOVEMBER 21, 2020

It also addresses the question of whether or not the presence of antibodies confers immunity to SARS-CoV-2, and makes recommendations on information to give to patients who have tested positive or negative. The post FIP expert group issues advice for pharmacists on COVID-19 tests appeared first on Pharma Mirror Magazine.

Documentation 52

Documentation Immunization 52

Pharmaceutical Technology

JUNE 6, 2025

This integration will reinforce Juvenescence’s pipeline in cardio-metabolism, cognition, immunity and cellular repair sectors. Can pharma tariffs “Make America Manufacture Again”? Incorporating Ro5’s AI platform into Juvenescence is expected to accelerate the development of AI-enabled treatments.

Communication 52

Communication Hospitals Packaging Compounding 52

Pharma Mirror

APRIL 8, 2022

The collaboration aims to build on a proprietary immune-based treatment for chronic inflammatory conditions being developed by Dr. John Foerster’s team at the University of Dundee. The goal of the partnership is to fully control the itch associated with skin conditions and achieve a prolonged and deep therapeutic effect for patients.

Immunization 52

Immunization 52

Pharma Mirror

JANUARY 18, 2022

The post Almirall and IRB Barcelona announce a research collaboration to discover novel molecular glue therapeutics for severe skin diseases appeared first on Pharma Mirror Magazine.

Immunization 52

Immunization 52

Pharma Mirror

DECEMBER 1, 2021

Preliminary data from prior small studies had suggested a potential benefit of interferon beta-1a, a natural antiviral component of the immune system, for COVID-19 patients. The post Emmes Announces Completion of Third ACTT Clinical Trial for COVID-19 appeared first on Pharma Mirror Magazine.

Immunization 52

Immunization Hospitals 52

Pharma Mirror

MARCH 17, 2021

today announced that both parties have entered into a research collaboration agreement aiming to create potential novel treatments for neurodegenerative disorders including Alzheimer’s disease (AD) which modulate immune competence in neurons and glia cells. Deutsches Zentrum fur Neurodegenerative Erkrankungen and Eisai Co.,

Immunization 52

Immunization 52

Pharmaceutical Technology

JUNE 23, 2025

June 23, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook HBM7020 activates immune system T cells to target and destroy B cells and plasma cells involved in many autoimmune diseases. Can pharma tariffs “Make America Manufacture Again”? Credit: luchschenF /Shutterstock.

Communication 52

Communication Hospitals Packaging Insurance 52

Pharmaceutical Technology

JUNE 12, 2025

The biotech used these funds to establish a pipeline that includes three metabolic disease programmes, with further assets across immune disorders and endocrine diseases. Can pharma tariffs “Make America Manufacture Again”? Apple Tree Partners founded the Deep Apple in 2022, investing $52m in series A funding.

Compounding 59

Compounding Communication Hospitals Packaging 59

Pharma Times

JUNE 18, 2025

The drug is being evaluated as both a monotherapy and in combination with Merck & Co’s Keytruda (pembrolizumab) for cancers such as melanoma, after demonstrating tumour regression, enhanced T-cell infiltration, and durable immune memory in preclinical studies. This field is required.

FDA 32

FDA Immunization 32

pharmaphorum

JULY 26, 2022

The concept of pre-emptively training the immune system to increase the frequencies of tumour-reactive T cells could be game-changing for cancer patients worldwide. For years, the promise of therapeutic cancer vaccines has intrigued researchers working in the oncology space. And for good reason.

Vaccines 52

Vaccines Immunization 52

pharmaphorum

AUGUST 18, 2022

Checkpoint inhibitors are a growing class of immunotherapy drugs that use monoclonal antibodies to activate checkpoint proteins, thus helping reactivate parts of the patient’s immune system that a cancer cell has shut down. The post Checkpoint inhibitors, Enhertu in spotlight as ASCO resumes in-person meetings appeared first on.

Chemotherapy 52

Chemotherapy Immunization 52

Pharmaceutical Technology

JUNE 25, 2025

RFK Jr has flip-flopped between endorsing and shunning the MMR vaccine , a shot that is proven to provide strong immunity against the disease. Can pharma tariffs “Make America Manufacture Again”?

Vaccines 64

Vaccines Hospitals Packaging Communication 64

Pharmaceutical Technology

JUNE 25, 2025

In a controversial move on 9 June 2025, US Secretary of Health and Human Services Robert F Kennedy Jr dismissed all 17 members of the Centers for Disease Control and Prevention (CDC) Advisory Committee for Immunization Practices (ACIP) that advises the federal government on vaccine safety. Can pharma tariffs “Make America Manufacture Again”?

Vaccines 52

Vaccines Packaging Hospitals Communication 52

Pharmaceutical Technology

JUNE 12, 2025

By GlobalData Learn more about Strategic Intelligence By covering a wide range of targets on malignant B cells, the therapy aims to enhance safety and efficacy while minimising the potential of tumour cells for developing immune-resistance mechanisms such as antigen escape. Can pharma tariffs “Make America Manufacture Again”?

Communication 52

Communication Hospitals Packaging Insurance 52

pharmaphorum

JUNE 8, 2021

If we work closely with government stakeholders and possibly collaborate on developing innovative access schemes for rare diseases, cancers, immune and inflammatory disorders, we can encourage greater participation by established biopharmas and stimulate the growth of entrepreneurial local companies in the region.”. About the author.

Chemotherapy 105

Chemotherapy Pharmaceutical Companies Pharmaceutical Companies Immunization 105

pharmaphorum

JULY 9, 2021

That’s according to Dr Gareth Parkes – a full-time gastroenterologist who co-founded Ampersand Health, which develops digital therapeutics for inflammatory bowel disease (IBD) and other immune mediated inflammatory diseases (IMIDs). Digital therapeutics in practice. About the interviewees. About Ampersand Health.

Hospitals 69

Hospitals Communication Immunization Pharmaceutical Companies 69

Pharmaceutical Technology

JUNE 20, 2025

Find out more This treatment involves obtaining immune cells from patients, modifying them in a laboratory setting then reintroducing them into patients’ bodies to destroy cancerous cells. Can pharma tariffs “Make America Manufacture Again”? Data Insights The gold standard of business intelligence.

Hospitals 52

Hospitals Communication Immunization Packaging 52

Pharmaceutical Technology

JUNE 11, 2025

CD4+T-cells and lymphocytes are both crucial elements of the immune system. Can pharma tariffs “Make America Manufacture Again”? Low levels of either increase the likelihood of infections and other health problems. HIV itself can reduce CD4 count – a value lower than 200 indicates acquired immunodeficiency syndrome (AIDS).

HIV Treatment and Prevention Agents 52

HIV Treatment and Prevention Agents FDA Communication Hospitals 52

pharmaphorum

JUNE 24, 2025

Vertex was also developing a version of the therapy called VX-264 in which the cells were encapsulated in a protective device designed to protect them from rejection by the immune system, but that failed to hit the mark in early clinical testing and has been dropped.

Pharmaceutical Companies 78

Pharmaceutical Companies Pharmaceutical Companies FDA Immunization 78

Pharmaceutical Technology

JUNE 16, 2025

A low incidence of immune effector cell-associated neurotoxicity syndrome was reported during the step-up dosing phase and the target dose phase. Can pharma tariffs “Make America Manufacture Again”? Two patients experienced dose-limiting toxicities and continued to receive the targeted dose.

Labelling 52

Labelling Communication Hospitals Vaccines 52

pharmaphorum

DECEMBER 23, 2022

In the last few years, the first generation of cell therapies has offered a powerful new way of treating blood cancers, with CAR-T technology reprogramming patients’ immune system to fight cancer.

Immunization 52

Immunization Hospitals Vaccines 52

Pharmaceutical Technology

JUNE 12, 2025

Amongst the new members on the CDC’s Advisory Committee for Immunization Practices (ACIP) are well-known vaccine sceptics and individuals who were critical of both the Covid-19 vaccines and related countermeasures such as lockdowns. Can pharma tariffs “Make America Manufacture Again”?

Vaccines 52

Vaccines Hospitals Communication Immunization 52

Pharma Mirror

OCTOBER 16, 2023

The first mRNA drug (BNT162b2 vaccine) was granted emergency use authorization by the FDA in December 2020 and approved for marketing in August 2021.

Immunization 52

Immunization Vaccines FDA 52

PharmaShots

MARCH 9, 2023

Birthplace: Belén was born in Almansa (Spain) Additional Information: Merck became a significant international participant in immunology, oncology, and immune oncology under her leadership of the Healthcare business. and Banco Bilbao Vizcaya Argentaria S.A " LinkedIn Total experience: 29 yrs. LinkedIn Total experience: 31 yrs.

FDA 40

FDA Pharmaceutical Companies Pharmaceutical Companies Immunization 40

Pharmaceutical Technology

JUNE 18, 2025

fired 17 sitting members of the Advisory Committee on Immunization Practices at the Centers for Disease Control and Prevention (CDC), concerns rose about the stance of federal agencies on vaccines. Can pharma tariffs “Make America Manufacture Again”?

FDA 52

FDA Vaccines Communication Hospitals 52

ISPE

OCTOBER 27, 2022

This can be challenging for many reasons: it can be difficult to estimate the size and number of polynucleotides to transfer, the efficiency of the vector in the particular cells addressed, the scale of production required, and whether a patient’s immune system will respond to vector particles as a microorganism. Accessed 11 August 2022.

Packaging 52

Packaging Communication Immunization Vaccines 52

pharmaphorum

JANUARY 21, 2021

But could digital immunity passports be the answer? Tan, the chief strategy officer at Immunization Action Coalition, told CNBC: “I think it’s premature to be talking about how we get people these immunisations certificates. He has been a journalist since the 1990s and has written for websites, newspapers and magazines.

Vaccines 85

Vaccines Immunization Hospitals 85

Pharmaceutical Technology

JUNE 16, 2025

Keytruda is designed to enhance the immune system’s ability to detect and combat tumour cells. Can pharma tariffs “Make America Manufacture Again”? Based on these trial results, Keytruda as part of this regimen shows potential to change long-standing standards of care for treating certain patients with locally advanced HNSCC.”

FDA 52

FDA Research Laboratories Communication Hospitals 52

pharmaphorum

AUGUST 13, 2020

New York Magazine , the New York Times and The Economist amongst many other news organisations knocked down their paywalls for COVID-19-related coverage to keep readers informed in a rapidly changing and often confusing environment. In Britain, the venerable BBC launched BBC Bitesize to help parents home-school children.

Health and Personal Care Stores 112

Health and Personal Care Stores Vaccines Communication Pharmaceutical Companies 112

Pharmaceutical Technology

JUNE 13, 2025

This approval was supported by results from Moderna’s Phase III study (NCT06067230), which demonstrated the vaccine’s immune response worked just as well in this age group compared to the existing approved age group of 60 years and older. Can pharma tariffs “Make America Manufacture Again”?

Vaccines 52

Vaccines FDA Labelling Communication 52

pharmaphorum

SEPTEMBER 1, 2020

George Merck on the cover of Time magazine. In cancer, the pharma industry has begun producing immunotherapies, which do not act directly against the disease but instead enlist the immune system to fight against malignant tissues. Thalidomide and the development of drug safety regulation and monitoring.

FDA 145

FDA Immunization Vaccines 145

pharmaphorum

JUNE 18, 2025

R&D Going wide on immune system activation, with Jeffrey Meckler Indaptus CEO Jeff Meckler discusses his companys unconventional approach to immunotherapy, based on activating a wide swath of the immune system.

Pharmaceutical Companies 88

Pharmaceutical Companies Pharmaceutical Companies Immunization FDA 88

Pharmaceutical Technology

JUNE 10, 2025

The US department of Health and Human Services (HHS) has culled the 17 Biden-appointed members on the Advisory Committee for Immunization Practices (ACIP) at the Centers for Disease Control and Prevention (CDC) in a move observers warn is liable to further fuel the spread of vaccine-preventable illnesses. lev radin via Shutterstock.

Vaccines 52

Vaccines FDA Immunization Communication 52